Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis

Journal of Clinical Investigation

Volumn 97, Issue 3, 1996, Pages 728-735

  Friedlander, Miriam A ^a   Wu, Yu Ching ^a   Elgawish, Abdelhamid ^a   Monnier, Vincent M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

furosine; hemodialysis; pentosidine; peritoneal dialysis; peritoneal transport

Indexed keywords

GLYCOSYLATED PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MOLECULAR WEIGHT; PERITONEAL DIALYSIS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN GLYCOSYLATION;

EID: 13344269006     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118471     Document Type: Article

References (25)

1. Sell, D.R., and V.M. Monnier. 1990. End stage ienal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen J. Clin. Invest. 85:380-384.
2. Vlassara, H., R. Bucala, and L. Striker. 1994. Pathogenic effects of advanced glycosylation: biochemical, biological, and clinical implications for diabetes and aging. J Lab. Invest. 70:138-151.
3. Sell, D.R., and V M Monnier. 1989 Structural elucidation of a fluorescent cross link from human senescent extracellular matrix: implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602.
4. McCance, D.R., D.G. Dyer, J.A. Dunn, K.E. Bailie, S.R Thorpe, J.W. Bayacs, and T J. Lyons. 1993. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 91:2470-2478.
5. Beisswenger, P J., L.L. Moore, T. Brinck-Johnson, and T.J Curphey. 1993. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin. Invest. 92:212-217.
6. Hricik, D.E., J.A. Schulak, D.R. Sell, J F. Fogarty, and V.M. Monnier. 1993. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int. 43:398-403.
7. Friedlander, M.A., Y.C Wu, J.A. Schulak, V M. Monnier, and D.A. Hricik. 1995. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am. J. Kidney Dis. 25: 441-451.
8. Wu, Y.C , V Monnier, and M. Friedlander. 1995. Reliable determination of furosine in human serum and dialysate proteins by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 667 328-332.
9. Takahashi, M , T. Ohishi, H. Aoshima, K. Kawana, K. Kushid, T. Inoue, and K. Horiuchi. 1993. The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia. 36:664-667.
10. Takahashi, M , K. Kushida, K Kawana, C. Ishihara, M. Denda, T. Inoue, and K. Horiuchi. 1993. Quantification of the cross-link pentosidine in serum from normal and uremic subjects. Clin. Chem. 39:2162-2165.
11. Odetti, P., J. Fogarty, D.R. Sell, and V.M. Monnier. 1992. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes. 41:153-159.
12. Resmini, P., L. Pelligrino, and G. Batelli. 1990. Accurate quantification of furosine in milk and dairy products by a direct HPLC method. Ital. J. Food Sci 3:173-183.
13. Korbet, S.M., Z. Makita, C.A. Firanek, and H. Vlassara. 1993. Advanced glycosylation end products in CAPD patients. Am. J. Kid. Dis 22:588-591.
14. Anderson, S.S., E C Tsilibary, and A.S. Charonis. 1993. Nonenzymatic glycation induced modifications of intact bovine kidney tubular basement membrane. J Clin. Invest. 92:3045-3052.
15. Giardino, I , D. Edelstein, and M. Brownlee. 1994. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J. Clin. Invest. 94:110-117.
16. Kaysen, G.A., and P. Schoenfeld. 1984. Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int. 25: 107-114.
17. Cohen, M.P., E. Hud, and V.Y. Wu 1994. Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. Kidney Int. 45:1673-1679.
18. Williams, S.K., J J. Devenny, and M.W. Bitensky. 1981. Micropinocytotic ingestion of glycosylated albumin by isolated microvessels: possible role in the pathogenesis of diabetic microangiopathy. Proc. Natl. Acad. Sci USA. 78: 2393-2397.
19. Williams, S.K., and N J. Solenski. 1984. Enhanced vesicular ingestion of nonenzymatically glycosylated proteins by capillary endothelium Microvasc. Res. 28:311-321.
20. Williams, S.K., and R.K. Siegal. 1985. Preferential transport of nonenzymatically glycosylated ferritin across the kidney glomerulus. Kidney Int. 28:146-152.
21. Dulaney, J.T., and F.E. Hatch. 1984. Peritoneal dialysis and loss of proteins: a review. Kidney Int. 26:253-262.
22. Makita, Z., S. Radoff, E.J. Rayfield, Z. Yang, E. Skolnik, V. Delaney, E.A. Friedman, A. Cerami, and H. Vlassara. 1991. Advanced glycosylation end products in patients with diabetic nephropathy N. Engl J. Med. 325:836-842.
23. Makita, Z., R. Bucala, E.J. Rayfield, E.A Friedman, A.M. Kaufman, S.M. Korbet, R.H. Barth, J.A. Winston, H. Fuh, K.R. Manogue, et al. 1994. Reactive glycosylation end products in diabetic uremia and treatment of renal failure. Lancet. 343:1519-1522.
24. Papanastasiou, P., L. Grass, H Rodela, A Patrikarea, D. Oreopoulos, and E P. Diamandis. 1994. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int. 46:216-222
25. Vlassara, H 1994. Serum advanced glycosylation end products, a new class of uremic toxins? Blood Purif 12:54-59.